1. Home
  2. NBY vs NXTC Comparison

NBY vs NXTC Comparison

Compare NBY & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovaBay Pharmaceuticals Inc.

NBY

NovaBay Pharmaceuticals Inc.

HOLD

Current Price

$1.95

Market Cap

31.6M

Sector

N/A

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$12.77

Market Cap

35.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBY
NXTC
Founded
2000
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.6M
35.9M
IPO Year
2007
2019

Fundamental Metrics

Financial Performance
Metric
NBY
NXTC
Price
$1.95
$12.77
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
764.8K
33.3K
Earning Date
05-14-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
35.42
N/A
EPS
0.76
N/A
Revenue
$370,000.00
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.31
52 Week High
$19.95
$15.74

Technical Indicators

Market Signals
Indicator
NBY
NXTC
Relative Strength Index (RSI) 57.82 63.93
Support Level $1.01 $10.73
Resistance Level $2.52 $14.01
Average True Range (ATR) 0.26 1.08
MACD 0.11 0.30
Stochastic Oscillator 96.45 86.45

Price Performance

Historical Comparison
NBY
NXTC

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: